Today, we shared some big news! Medtronic announced its intent to separate our Diabetes business into a standalone, public company. This next chapter enables us to relentlessly focus and accelerate strategic investments in areas that will most benefit you — from breakthrough innovations, five-star customer experience to scaling automated manufacturing to meet growing demand for our technologies. We’re unique in Medtronic as a direct-to-consumer business so this is a win-win as it allows both companies to strategically focus on our core strengths.

I wanted to personally reach out regarding the recent approval of our Simplera Sync™ sensor. While this should have been a moment of celebration, I understand many of you were disappointed by our communication. Over the past few days, I’ve had the privilege of speaking with many of you and listening to your concerns.